Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18154696 | 0.84 | LMNA (0.36) | LMNAPOLB | |
| SCHEMBL30353134 | 0.84 | LMNA (0.36) | LMNAPOLB | |
| SCHEMBL18154782 | 0.84 | HSP90AA1 (0.33) | LMNA | |
| SCHEMBL18154846 | 0.78 | MTOR (0.41) | — | |
| SCHEMBL18154672 | 0.78 | KDM4E (0.32) | KDM4ELMNA | |
| SCHEMBL18154843 | 0.77 | RAB9A (0.34) | KDM4E | |
| SCHEMBL18154735 | 0.72 | HTR6 (0.42) | KDM4ELMNA | |
| SCHEMBL30353164 | 0.70 | PIK3C3 (0.42) | LMNA | |
| SCHEMBL18154717 | 0.70 | PIK3C3 (0.42) | LMNA | |
| SCHEMBL18154795 | 0.68 | NAMPT (0.38) | LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11612604-B2 | Methods of treating cancer with PLK4 inhibitors | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2023-03-28 | — | — | US | disclosed |
| EP-3283482-A1 | PLK4 INHIBITORS | Ludwig Institute for Cancer Research Ltd (CH) | 2018-02-21 | — | — | EP | disclosed |
| WO-2016166604-A1 | PLK4 INHIBITORS | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11612604-B2 | Methods of treating cancer with PLK4 inhibitors | PLK4, PLK2, PLK3 | KDM4E 893/4885GLA 1272/4885LMNA 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.